Analysis indicates that Abbott's second-quarter diagnostics sales grew by 42% to $3.09 billion, exceeding the expected $3.02 billion, and the company reiterated its full-year comparable sales growth guidance of 6.5% to 7.5% for 2026. Thermo Fisher Scientific's organic revenue increased by 5%, with its analytical instruments business resuming growth, leading the company to raise its earnings guidance. The article compares the investment prospects of the two companies, suggesting that Abbott's investment value lies in the stable growth of its diversified businesses, while Thermo Fisher Scientific relies on the cyclical recovery of the life sciences industry.